Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of
innovative therapies for diseases and conditions of the eye, today announced that it will present at three upcoming investor
conferences:
- 2017 BIO CEO & Investor Conference
Monday, February 13, 2017 at 8:30 a.m. Eastern Time
The Waldorf Astoria New York, New York, NY
- 2017 RBC Capital Markets Global Healthcare Conference
Thursday, February 23, 2017 at 9:00 a.m. Eastern Time
The New York Palace Hotel, New York, NY
- 37th Annual Cowen and Company Healthcare Conference
Monday, March 6, 2017 at 2:40 p.m. Eastern Time
The Boston Marriott Copley Place, Boston, MA
Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at
investors.ocutx.com. Replays of the webcasts will be available on the Company's website for two weeks following each
presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a new
drug application (NDA) for post-surgical pain for its lead product candidate, DEXTENZA, which has completed Phase 3 clinical
development for post-surgical ocular inflammation and pain. Subject to the approval of the NDA for post-surgical ocular pain,
Ocular Therapeutix intends to submit a supplemental NDA for DEXTENZA to broaden its label to include an indication for
post-surgical inflammation. DEXTENZA is also in Phase 3 clinical development for allergic conjunctivitis. OTX-TP is in Phase 3
clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots
for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Medical Dynamics
Cynthia Sutherland, 646-599-8635
Media Group Director
csutherland@rxmedyn.com
or
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Marketing & Commercial Operations
scorning@ocutx.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005863/en/